TABLE 2

Baseline and After 1 Cycle of Chemotherapy, TGV and SUVmax Values for All Patients, Grouped According to CT Response

Status	Sex	Age (y)	TGV0	TGV1	TGV1/TGV0 (%)	SUV0	SUV1	SUV1/SUV0 (%)	Survival (mo)
CT PR
1	M	69	278	138	50	5.6	4.0	71	23.7^†
2	M^*	67	1,100	177	16	13.9	7.5	54	8.0
3	F	61	16,101	4,814	30	13.2	7.5	57	18.7^†
4	M	69	7,205	1,130	16	11.5	8.3	72	11.5
5	M	71	9,840	1,089	11	13.1	5.1	39	10.3^†
6	M	66	3,372	2,033	60	12.2	7.4	61	3.9^†
7	F	65	549	390	71	5.4	3.2	59	4.4^†
CT SD
8	M	68	9,177	10,412	113	12.8	12.2	95	4.9
9	M	55	4,701	5,012	107	5.5	4.5	82	1.4
10	M	63	5,139	5,057	98	9.0	8.7	97	6.9
11	M	68	3,048	2,268	74	18.1	14.0	77	9.5
12	M	54	5,631	3,762	67	9.0	6.8	76	17.6
13	M	64	4,398	2,862	65	13.0	6.8	52	5.9
14	M^*	60	15,809	11,104	70	13.6	11.1	82	14.5^†
15	M	55	3,104	265	8	9.3	3.7	40	12.4^†
16	F	71	1,413	1,470	104	13.2	10.6	80	9.9
17	M	74	5,484	3,440	63	10.9	10.2	94	6.2^†
18	M	65	9,635	7,754	80	13.0	10.4	80	5.9
19	M	75	897	423	47	17.8	7.5	42	2.9^†
20	M	54	5,056	3,574	71	10.0	11.1	111	2.5^†
CT nonmeasurable
21	M	52	853	861	101	5.3	4.9	92	7.5
22	M	73	834	689	83	7.5	7.7	103	12.2
23	M	67	n/e	n/e	n/e	n/e	n/e	n/e	8.4^†

↵* Previous talc pleurodesis.
↵† Survival at time of censorship (alive).
TGV0 = TGV at baseline (before chemotherapy); TGV1 = TGV after 1 cycle of chemotherapy; TGV1/TGV0 (%) = TGV after 1 cycle of chemotherapy divided by baseline TGV value and expressed as a percentage; SUV0 = SUVmax at baseline (before chemotherapy); SUV1 =SUVmax after 1 cycle of chemotherapy; SUV1/SUV0 (%) = SUVmax after 1 cycle of chemotherapy divided by baseline SUVmax value and expressed as a percentage; n/e =not evaluable, as a VOI could not be generated on PET images.